CCL1-Ig Fusion Polypeptide for T Cell Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for graft-versus-host disease (GVHD) and autoimmune disorders are ineffective, as they fail to adequately suppress effector T cells, which are key contributors to these conditions.
Innovation Solution
Development of a CCL1-Ig fusion polypeptide that induces the production of CD4+ CD25+ Foxp3+ regulatory T cells, thereby suppressing effector T cells, using a method that involves contacting CD4+ Foxp3- T cells with the CCL1-Ig polypeptide in an ex-vivo biological sample, such as blood or bone marrow, to enhance regulatory T cell activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-inflammatory therapies (such as TNF-α neutralization) are used to treat GVHD, then some inflammatory autoimmune diseases are suppressed, but GVHD treatment fails
Solution Approach 1:
The patent applies local quality by targeting a specific pathway (CCL1-CCR8 axis) that is locally relevant to GVHD pathogenesis rather than using broad-spectrum anti-inflammatory agents. The CCL1-Ig fusion protein specifically addresses the chemokine-mediated T cell recruitment and activation that occurs in GVHD, providing disease-specific therapeutic action while sparing other immune functions.
Solution Approach 2:
The patent segments the immune response into distinct functional components by targeting CCL1-mediated chemokine signaling separately from other inflammatory pathways. This segmentation allows selective modulation of pathogenic T cell responses while preserving beneficial immune functions, explaining why therapies targeting other pathways (like TNF-α) fail in GVHD.
2Reliability
If effector T cell activity is not suppressed, then immune response remains strong, but GVHD and autoimmune diseases progress
Solution Approach 1:
The patent uses CCL1-Ig as an intermediary molecule that binds to CCL1 and prevents its interaction with CCR8 receptors on T cells. This intermediary approach blocks the signaling pathway that leads to effector T cell activation and tissue injury, thereby controlling disease progression while using a physiologically relevant mechanism rather than direct cytotoxic approaches.
3Reliability
If regulatory T cells are not induced, then effector T cell function remains unchecked, but inducing T-regs requires specific cytokine environments
Solution Approach 1:
The patent extracts the key function of regulatory T cell induction (suppression of effector T cells) from the complex cytokine environment required for its generation. By directly blocking CCL1-CCR8 interactions, the therapy achieves T cell suppression without requiring the complex Th3 or Tr1 cytokine polarization conditions, simplifying the therapeutic approach while maintaining effectiveness.
Data Source
AI summary
A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.